MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

AbCellera Biologics Inc

Fechado

SetorSaúde

3.54 3.21

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.5

Máximo

3.54

Indicadores-chave

By Trading Economics

Rendimento

48M

-8.9M

Vendas

36M

45M

Margem de lucro

-19.942

Funcionários

562

EBITDA

22M

-18M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+101.41% upside

Dividendos

By Dow Jones

Próximos Ganhos

11 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

121M

1B

Abertura anterior

0.33

Fecho anterior

3.54

Sentimento de Notícias

By Acuity

50%

50%

156 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

AbCellera Biologics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de abr. de 2026, 17:04 UTC

Grandes Movimentos do Mercado

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

11 de abr. de 2026, 08:20 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

11 de abr. de 2026, 00:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Big Yachts, Big Bucks -- Barrons.com

10 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 de abr. de 2026, 21:01 UTC

Ganhos

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 20:31 UTC

Conversa de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 de abr. de 2026, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 de abr. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 de abr. de 2026, 18:25 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Finish With Weekly Gains -- Market Talk

10 de abr. de 2026, 18:05 UTC

Conversa de Mercado

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 de abr. de 2026, 17:26 UTC

Ganhos

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 de abr. de 2026, 17:10 UTC

Conversa de Mercado

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 de abr. de 2026, 17:00 UTC

Notícias Principais

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

10 de abr. de 2026, 16:12 UTC

Ganhos

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 de abr. de 2026, 16:11 UTC

Ganhos

Partners Group: Traditional Programs Contributed $3.3B

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group 1Q New Client Demand $8.3B

Comparação entre Pares

Variação de preço

AbCellera Biologics Inc Previsão

Preço-alvo

By TipRanks

101.41% parte superior

Previsão para 12 meses

Média 7.13 USD  101.41%

Máximo 11 USD

Mínimo 3.52 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para AbCellera Biologics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.99 / 2.635Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

156 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat